Nonselective Beta-Blockers in Portal Hypertension: Why, When, and How?

Описание к видео Nonselective Beta-Blockers in Portal Hypertension: Why, When, and How?

Anahita Rabiee M.D., Guadalupe Garcia-Tsao M.D., F.R.C.P., Elliot B. Tapper M.D.

First published: 08 March 2022
https://doi.org/10.1002/cld.1182

This study was supported by the National Institutes of Health through National Institute of Diabetes and Digestive and Kidney Diseases (grant 1K23DK117055-01A1 to E.B.T.).
Potential conflict of interest: E.B.T. consults for Novartis and Allergan, advises Mallinckrodt and Bausch Health, and has received grants from Gilead and Valeant.

Комментарии

Информация по комментариям в разработке